CanSinoBIO gets China nod for inhaled COVID-19 vaccine trial

China’s CanSino Biologics Inc (CanSinoBIO) said on Tuesday it won approval for a clinical trial in the country to develop a COVID-19 vaccine for inhalation.

The National Medical Products Administration approved the trial of the vaccine, jointly developed by CanSinoBIO and the Beijing Institute of Biotechnology, the company said.

The company’s COVID-19 vaccine for injection was recently approved for emergency use in Hungary.

• Latest coronavirus numbers: Hungary records highest ever daily COVID death toll
• Hungary’s medicines authority: Strict regulations must be met for new vaccines from India and China